Viridian Q1 cash $636.6M; veligrotug BLA on track for H2 2025

Viridian Therapeutics, Inc.\DE

Cash, cash equivalents, and short-term investments $636.6M at March 31, 2025, down from $717.6M in December 2024; runway into H2 2027.
R&D expenses $76.8M in Q1 2025 vs $40.9M in Q1 2024, driven by more clinical trials and increased headcount.
Veligrotug BLA submission to FDA on track for H2 2025; EMA MAA expected in H1 2026.
Phase 3 topline data for VRDN-003 (subcutaneous TED) expected H1 2026 from REVEAL-1 and REVEAL-2 trials.
VRDN-006 phase 1 healthy volunteer data expected Q3 2025; VRDN-008 IND submission targeted for year-end 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.